High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.

High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009 Dec; 94(12):1669-75.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Benzamides
Cross-Over Studies
Cytarabine
Diarrhea
Drug Administration Schedule
Edema
Humans
Imatinib Mesylate
Interferon-alpha
Kaplan-Meier Estimate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Muscle Cramp
Nausea
Piperazines
Pyrimidines
Remission Induction
Survival Rate
Treatment Outcome

authors with profiles

Richard A. Larson